Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

about

Other targeted drugs in melanoma Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.Uncarboxylated Osteocalcin Induces Antitumor Immunity against Mouse Melanoma Cell Growth.

P2860

Q26775594-9A246999-7CD2-4A2F-9818-6DBB5FCD209D Q36279825-67AACCB7-3EAA-407B-BD45-6B72DB343308 Q41243255-D56B75A3-0F49-417B-AF48-F2653736BACB

P2860

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

Item

http://www.wikidata.org/entity/Q53064579

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

@en

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

@nl

type

Item

label

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

@en

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

@nl

prefLabel

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

@en

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

@nl

P1476

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

@en

P2093

Jill T Johnson

http://www.w3.org/2001/XMLSchema#string

Laura F Hutchins

http://www.w3.org/2001/XMLSchema#string

Lindsey E Dayer

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

Pazopanib: a novel multitargeted tyrosine kinase inhibitor.

Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.

Phase I trial of pazopanib in patients with advanced cancer.

Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.

P304

224-231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155214524084

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260430077

http://www.w3.org/2001/XMLSchema#string

P698

24576945

http://www.w3.org/2001/XMLSchema#string

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

about

P2860

P2860

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698